Consorci Sanitari Integral — Clinical Trial Site

25 Registered trials

8 Currently recruiting

Organisation

Consorci Sanitari Integral

Location

L'hospitalet De Llobregat, Spain

Identifier

ORG-100045756

Address

Dos De Maig 301, 08025, Spain

Departments

#2313: servicio de neurología
#3400:Oncología
034034: Oncología
3140: medicina interna
Cardiology
Hematología
Hospital de Sant Joan Despí
Hospital Moises Broggi - Servicio Oncologia
Medical Oncology
NA
Nephrologist
Oncology
Ophtalmology
Ophthalmology
Servicio de Aparato Digestivo
Servicio de Oncología
Vascular Risk Area

Clinical trials at this site (25)

Search interface

Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial) Pending

2024-515240-24-00 Locally advanced rectal cancer 4
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm… Recruiting

2024-515853-48-00 advanced/metastatic non-squamous non-small cell lung ca 5 2025-09-05
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting

2024-512161-14-00 Breast Cancer 3 2025-01-14
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
Phase II study of Atezolizumab plus Tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal… Ended

2023-509485-38-00 Squamous cell carcinoma of the anal canal 4 2023-03-29
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore… Ended

2024-514891-41-00 HR+, HER2- advanced or metastatic breast cancer 6 2022-07-19
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended

2023-507130-24-00 Neovascular age-related macular degeneration (nAMD) 5 2021-10-22
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
Atacicept in Subjects with IgA Nephropathy (ORIGIN and ORIGIN 3) Ended

2023-503772-24-00 IgA Nephropathy 10 2021-09-15
A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast… Ended

2024-514733-38-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2020-11-03
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study Halted

2024-518951-52-00 Worsening Heart Failure 4 2025-11-12
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended

2022-500746-16-00 Geographic Atrophy 4 2023-08-11
Study to evaluate the efficacy and safety of cetuximab plus irinotecan compared to investigator's choice therapy in patients with metastatic… Ended

2024-518728-59-00 metastatic colorectal cancer 4 2020-10-23
OXU-001 compared to Intravitreal Ozurdex for the Treatment of Diabetic Macular Edema Ended

2023-503496-17-00 Diabetic Macular Edema (DME) 4